Authored By: Amit Gupta, MD, Leeford Healthcare India has firmly established itself as the backbone of the global generic pharmaceutical industry. Supplying over 20% of the world’s generics, the country plays a pivotal role in making essential medicines accessible and affordable worldwide. Valued at $50 billion, the Indian pharmaceutical sector continues to grow, fueled by cost efficiency, cutting-edge manufacturing capabilities, and a highly skilled workforce. However, as the global landscape evolves, India’s generics industry must navigate new challenges and seize emerging opportunities to maintain its dominance. Key Drivers of India’s Generic Pharma Boom Government Support & Policy Interventions Strategic initiatives like the Production Linked Incentive (PLI) schemes, ‘Make in India,’ and financial incentives for bulk drug production have strengthened India’s pharmaceutical backbone. These policies have not only encouraged domestic manufacturing but have also made India a preferred global supplier. Cost Advantage and Competitive Manufacturing India’s ability to manufacture high-quality medicines at significantly lower costs than developed markets remains a game-changer. This advantage stems from efficient production processes, economies of scale, and cost-effective skilled labor, ensuring that Indian generics remain globally competitive. Strong Export Market With exports spanning over 200 countries, including the U.S., Europe, and Africa, India has cemented its reputation as the “Pharmacy of the World.” The demand for high-quality, affordable generics continues to rise, opening new avenues for Indian pharmaceutical companies to expand their global footprint. R&D and Innovation in Complex Generics The shift toward biosimilars, complex generics, and high-value formulations signals a transformative phase for the industry. Indian pharma firms are increasingly investing in research and development to manufacture next-generation generics, ensuring they stay ahead of regulatory and market dynamics. Challenges Hindering Future Growth Regulatory Hurdles Global regulatory bodies, particularly the U.S. FDA, EMA, and TGA, have intensified scrutiny of Indian pharmaceutical manufacturing units. Frequent plant inspections and compliance requirements demand a renewed focus on quality control and regulatory preparedness. Price Control Policies and Profitability Concerns Government-imposed price capping by the National Pharmaceutical Pricing Authority (NPPA), while ensuring affordability, continues to squeeze margins for pharma companies. Striking a balance between public health and industry sustainability remains a pressing challenge. Patent Litigations & Market Entry Barriers As Indian companies move into complex generics and biosimilars, they face growing patent litigation and legal challenges from Big Pharma, creating obstacles for market entry in regulated regions. Dependence on China for APIs Despite being a pharmaceutical powerhouse, India remains heavily reliant on Active Pharmaceutical Ingredients (APIs) from China, posing a significant supply chain risk. Strengthening domestic API production is crucial for long-term sustainability and independence. The Road Ahead: Future Trends & Opportunities Expansion into Specialty Generics & Biosimilars The future of Indian generics lies in high-value, specialty generics and biosimilars. With global patents expiring, Indian firms have a massive opportunity to fill gaps in the market with cost-effective alternatives. AI & Digital Transformation in Pharma Artificial intelligence (AI), machine learning-driven drug discovery, and automation in manufacturing are set to revolutionize the pharmaceutical industry. Indian pharma firms investing in digital innovation will gain a competitive edge in precision medicine and optimized supply chain management. Achieving Self-Sufficiency in API Manufacturing To reduce dependence on China, Indian companies must focus on domestic API production, fermentation-based drug manufacturing, and government-backed incentives to build a resilient supply chain. Global Collaborations & Strategic Partnerships Joint ventures with international pharma giants, strategic alliances for contract manufacturing, and co-development partnerships will pave the way for Indian firms to penetrate new markets and expand their global reach. Sustainability and Green Pharma Practices The industry must actively adopt eco-friendly manufacturing processes, reduce carbon footprints, and implement waste management solutions to align with global environmental regulations and investor expectations. India’s Role in the Future of Global Healthcare As India moves towards becoming a $130 billion pharmaceutical market by 2030, its role in shaping global healthcare remains undeniable. However, balancing affordability with profitability, ensuring regulatory compliance, and innovating beyond traditional generics will determine the future trajectory of the industry. Leeford’s Vision for the Future At Leeford Healthcare, we are committed to navigating these evolving industry dynamics with a focus on innovation, quality, and sustainability. By investing in cutting-edge R&D, reinforcing compliance standards, and embracing digital transformation, we aim to contribute meaningfully to India’s next phase of growth in the generics sector. Our vision is to provide affordable, high-quality medicines while staying ahead of global healthcare trends. India’s pharmaceutical boom is far from over, but the next phase demands strategic foresight, agility, and bold action. The question is no longer whether India will remain the world’s leading generics supplier, but rather, how it will redefine the future of global healthcare.

In the world of medicine and fitness, few names resonate as powerfully as Dr. Mahesh Kumar. With 25 years of unparalleled expertise, Dr. Kumar has not only demystified the complex science of anabolic steroids but has also set new benchmarks in education, consulting, and innovation. His journey is a testament to dedication, vision, and an unwavering commitment to empowering others with knowledge. From authoring the world’s first book on anabolic steroids pharmacology to setting three world records, Dr. Kumar has carved a legacy that continues to inspire millions. A Journey of Education, Consulting, and World Records Dr. Mahesh Kumar’s journey began in 1998 when he started educating people about anabolic steroids through seminars, lectures, and certification programs. His mission was clear: to break down the myths and misinformation surrounding steroids and provide science-based knowledge to doctors, fitness trainers, athletes, and the general public. Over the years, he has trained thousands of individuals, transforming complex scientific concepts into simple, practical insights. His interactive and engaging teaching style has made him a sought-after expert in both medical and fitness circles. In 2006, Dr. Kumar took his mission a step further by launching consulting services for steroid users. Recognizing the health risks associated with steroid misuse, he offered expert advice on managing side effects, conducting comprehensive health check-ups, and ensuring long-term physical, mental, and hormonal well-being. His holistic approach has made him a trusted advisor, saving countless lives and helping users achieve their fitness goals safely. The World’s First Book on Anabolic Steroids Pharmacology For decades, anabolic steroids were shrouded in myths and misconceptions. Dr. Mahesh Kumar saw the need for a reliable, science-based resource and authored the world’s first book on anabolic steroids pharmacology, titled Uncover the Secrets of Anabolic Steroids Pharmacology. This groundbreaking 57-page book, featuring over 13,000 words, delves into topics such as how steroids work in the body, their effects on bones and the brain, their applications in sports and medicine, and methods for detecting their use. “This book is not just about steroids; it’s about understanding the science behind them,” says Dr. Kumar. His goal was to provide accurate, accessible information and dispel common misconceptions. The book has since become an essential resource for fitness enthusiasts, medical professionals, and researchers alike, setting a new standard in steroid education. The Impact: A Legacy in Science and Education Dr. Mahesh Kumar’s contributions have transformed the way anabolic steroids are perceived and understood. Some key milestones in his illustrious career include: 1998: Began teaching about anabolic steroids, sparking a nationwide educational revolution. 2006: Launched consulting services to help steroid users stay safe and healthy. 2024: Published the world’s first book on anabolic steroids pharmacology. Founded Medifit Education, a platform dedicated to training the next generation of fitness and medical professionals. Through his seminars, Dr. Kumar has helped countless individuals build successful careers in fitness and medicine. His consulting services have not only improved health outcomes but also saved lives. And his book has become a cornerstone of steroid education, bridging the gap between science and practical application. Three World Records: A Testament to Excellence Dr. Mahesh Kumar’s passion for education and innovation is unparalleled. His dedication to sharing knowledge has earned him three world records, cementing his status as a global leader in medical and fitness education: 10,000 Certificate Courses: He has offered 10,000 courses in medical and fitness education, equipping learners with specialized knowledge. 10,000 E-Books: He created a digital library of 10,000 e-books, making advanced research accessible to all. 10,000 Educational Study Videos: He produced 10,000 videos explaining complex topics in a simple, engaging manner, benefiting learners worldwide. These records are a testament to Dr. Kumar’s commitment to making education accessible and impactful. The Future: Building on a Legacy Dr. Mahesh Kumar’s work is far from over. He envisions expanding his educational programs globally, authoring more books, and conducting cutting-edge research on hormone-related therapies. As a visionary, teacher, and scientist, he is not only shaping the present but also building the future of anabolic steroids pharmacology, consulting, and education. Dr. Mahesh Kumar: A Name That Made History Dr. Mahesh Kumar’s career is more than a list of achievements—it’s a legacy. From setting world records to writing groundbreaking books, he has become a global authority in anabolic steroids pharmacology. His focus on truth, science, and education has set a new standard for medical and fitness knowledge. For anyone seeking to understand the science of steroids, his book is a must-read. For those in need of expert advice, his consulting services are invaluable. Dr. Mahesh Kumar is not just a name; he is a symbol of excellence, innovation, and empowerment.

New Delhi: Microsoft, an American multinational technology company, is planning to shut down its video conferencing platform, Skype. According to a report from XDA, a message in the latest Skype for Windows preview reveals that the service will no longer be available starting in May. This marks the end of an era for a platform that revolutionized online communication. This decision will bring an end to Skype’s 22-year journey as it was first launched in 2003 and acquired by Microsoft in 2011. Over time, Microsoft gradually removed several features, including the discontinuation of Windows Live Messenger. In 2015, Microsoft attempted to integrate Skype into Windows 10. However, the effort lasted only nine months. Skype faced internal competition when Microsoft launched Teams in 2017. Teams was created to rival platforms like Slack, which are widely used by companies for internal communication. For years, there have been ongoing speculations about when Skype will be shut down. Teams will soon replace Skype The preview message indicates that Skype users will be prompted to switch to Teams, with a message reading, “Continue your calls and chats in Teams.” The message will also inform users that many of their contacts have already moved to Teams free, based on their Windows-integrated contacts. Users are expected to start seeing this notification in their Skype apps soon.

Samsung Galaxy A Series Price: South Korean giant Samsung has introduced the Galaxy A56, Galaxy A36 and Galaxy A26 smartphones in India and global markets. For the first time, the Galaxy A series comes with integrating Awesome Intelligence which includes Galaxy’s fan-favourite AI-powered features to reimagine creativity — while bringing enhanced durability and longevity, as well as robust security and privacy protections to provide a safe and long-lasting mobile experience.  Adding further, the Galaxy A26 5G comes with an IP67 dust and water resistance rating, offering robust protection against the elements for the first time. This brings it in line with the Galaxy A36 5G and Galaxy A56 5G, which also feature the same level of durability. The Samsung Galaxy A Series features an Object Eraser, enabling users to effortlessly remove unwanted distractions from their photos.  Notably, the pricing and availability of the Samsung Galaxy A26, Galaxy A36, and Galaxy A56 in India will be officially announced on March 3rd.   Samsung Galaxy A Series: Performance  The Samsung Galaxy A56 is the first phone to be powered by Exynos 1580 4nm SoC, and the Galaxy A36 uses a Snapdragon 6 Gen 3 SoC for the first time. Adding further, the Samsung Galaxy A26 sticks to the Exynos 1380. The Samsung Galaxy A56 and Galaxy A36 feature a larger vapour chamber.  Samsung Galaxy A Series: Software Updates  All the smartphones run Android 15 with One UI 7 out of the box and will get up to 6 generations of Android OS and One UI upgrades and 6 years of security updates.  Samsung Galaxy A Series: Camera  All the phones features a 50MP main lens with OIS. The A56 and A36 support 10-bit HDR recording on both the front and rear cameras. The Galaxy A56 5G features a 12MP ultra-wide lens, and the other two feature a 8MP ultra-wide lens. The A56 and A36 features a 5MP macro sensor, and the A26 has a 2MP macro sensor.  Samsung Galaxy A Series: Colour Options The Galaxy A56 5G comes in Awesome Lightgray, Awesome Graphite, Awesome Olive, and Awesome Pink, while the Galaxy A36 5G is available in Awesome Lavender, Awesome Black, Awesome White, and Awesome Lime. The Galaxy A26 5G offers classic shades of Black, White, Mint, and Peach Pink.  Samsung Galaxy A Series: Battery All the phones pack a 5,000mAh battery with A56 and A36 featuring support for 45W charging power and Super Fast Charge 2.0 technology, and the A26 sticks to 25W fast charging.  Samsung Galaxy A Series: Display  The Samsung Galaxy A56, A36, and A26 all feature a vibrant 6.7-inch FHD+ Super AMOLED display with a 120Hz refresh rate for smooth visuals. The A56 stands out with HDR support, up to 1900 nits peak brightness, and Corning Gorilla Glass Victus+ protection. The A26 features an Infinity-U design, while the A36 and A56 have Infinity-O displays.  Samsung Galaxy A Series: Price The Samsung Galaxy A56 5G is priced at $499.99 (approx. Rs 43,735) for the 8GB + 128GB variant and $549 (approx. Rs 48,000) for the 8GB + 256GB model. The Galaxy A36 5G starts at $399.99 (approx. Rs 34,990) for 6GB + 128GB, while the 8GB + 256GB version costs $415 (approx. Rs 36,205). The Galaxy A26 5G is available at $299.99 (approx. Rs 26,240) for 6GB + 128GB and $375 (approx. Rs 32,895) for 8GB + 256GB storage model. 

Vivo T4x 5G India Launch: After launching the Vivo V50 smartphone, the Chinese smartphone brand has announced the official launch date of the Vivo T4x 5G in the country. The phone is expected to have the largest battery in the segment. The Vivo T4x 5G may offered in two colour options: purple and blue. Moreover, the phone is said to come with a bunch of AI capabilities, with features like AI Erase, AI Photo Enhance, and AI Document Mode expected to be included.   Vivo T4x 5G India Launch Date And Availability The Vivo T4x 5G India launch date is set on March 5 at 12 pm. The phone will be available on Flipkart, Vivo online shop and other retailers. The phone is likely to intensify the competition in the sub- Rs 15,000 price bracket, going head to head with the likes of CMF Phone 1, iQOO Z9x and more.   Vivo T4x 5G Price In India (Expected) The phone is expected to be priced at 12,499 for the base trim while the 6GB RAM variant may be priced at Rs 13,999 while the 8GB RAM variant could be priced at Rs 15,499.  Vivo T4x 5G Specifications (Expected) The Vivo T4x 5G is expected to feature a 6.67-inch FHD+ LCD panel with a smooth 120Hz refresh rate. The phone is expected to be powered by the Dimensity 7300 processor, running on an Android 15-based skin with a promise of two years of OS updates and three years of security patches. A substantial 6,500mAh battery is likely to keep the phone running for extended hours.  In the camera department, the smartphone may sport a dual rear setup, led by a 50MP primary sensor, while an 8MP front-facing camera is expected to handle selfies. 

On Tuesday, 25 February 2025, Justice Prathiba M. Singh of the Delhi High Court issued a landmark judgment against Amazon Technologies, Inc., ordering the company to pay $39 million (approximately ₹340 crore) in damages for the deliberate and wilful infringement of the well-known trademark Beverly Hills Polo Club (logo). This ruling marks one of the highest damages ever awarded in India’s intellectual property rights (IPR) case. The court found that Amazon, through its private label “Symbol,” had engaged in activities that infringed upon the trademark owned by Lifestyle Equities, the proprietor of the Beverly Hills Polo Club brand in India. 33.78 million, with an additional 5 million awarded for increased advertising and promotional expenses incurred due to the infringement. At the prevailing exchange rate, the total damages amounted to ₹336 crore. Furthermore, the court awarded Lifestyle full litigation costs of ₹3.23 crore (approximately $375,000), bringing the total payout to nearly ₹340 crore. The case stemmed from Amazon’s unauthorised use of a logo under its private label “Symbol,” which closely replicated the iconic ‘horse-and-polo player’ logo of Beverly Hills Polo Club. Alongside Amazon Technologies, the defendants included Cloudtail (a former subsidiary of an Amazon-held company) and Amazon Seller Services, which operates the online marketplace www.amazon.in. The court had initially granted an interim injunction in favour of Lifestyle on 12 October 2020, which was later confirmed on 20 April 2022. During the proceedings, Cloudtail admitted to selling goods bearing the infringing logo from 2015 until July 2020, with sales amounting to approximately ₹25 lakh. While Cloudtail and Amazon Seller Services participated in the case, Amazon Technologies initially chose not to be represented by counsel, despite being part of the same corporate group. Cloudtail later paid ₹4,78,484 in damages as decreed by the court. Amazon Seller Services was removed from the case as no substantive relief was sought against them beyond compliance with takedown orders. Lifestyle presented its case through five witnesses, including fact witnesses, market experts, and a damages expert. The court actively engaged with the evidence, questioning witnesses to assess the validity of the claims. The judgment highlighted that Amazon had sold apparel under the infringing logo at heavily discounted prices—ranging from ₹300 to ₹400—compared to the original Beverly Hills Polo Club products, which were priced between ₹2,500 and ₹4,000. This pricing strategy, the court noted, exacerbated the damage to Lifestyle’s brand and market position. The court also emphasized the evolving nature of trademark infringement in the digital age, coining the term “e-infringement” to describe violations occurring on online platforms. This case underscores the judiciary’s willingness to address modern challenges in IPR enforcement. Commenting on the judgment, Mr. Sidhant Goel, Senior Partner at SIM AND SAN, Attorneys At Law, who represented Lifestyle, stated, “This judgment demonstrates that Indian courts are prepared to award substantial damages when evidence is effectively presented. It sets a new benchmark in IPR disputes, surpassing the previous record of ₹217 crore in a patent infringement case.” Mr. Mohit Goel, a Senior Partner at SIM AND SAN, added, “This ruling is a watershed moment in Indian trademark jurisprudence, positioning India as a jurisdiction that enforces rights through meaningful damage awards. The key to this success was the strategic selection of independent experts to substantiate the damages claim.” Lifestyle was represented by Senior Advocate Mr. Gaurav Pachnanda and a team from SIM AND SAN, including Mr. Sidhant Goel, Mr. Mohit Goel, Mr. Deepankar Mishra, Mr. Abhishek Kotnala, Mr. Karmanya Dev Sharma, and Ms. Avni Sharma from Mr. Pachnanda’s chambers. This landmark decision reinforces the importance of protecting intellectual property rights and sets a precedent for future cases involving e-commerce platforms and trademark infringement.

WhatsApp is down for many users in India. Users were facing issues with sending and receiving messages. According to the internet app tracking site Downdetector, the issue started around 9.10 pm on Friday. Several users shared that what they thought was an issue with their wifi or data, turned out that the app was down in fact. The issue started resolving around 9.32, at least 20 minutes after the outage. Some users even reported facing issues with WhatsApp calls as well. As per the Downdetector, the most hit areas were Delhi, Mumbai, Hyderabad, Bengaluru and Chennai while minor outages were reported across India. According to the data on the DownDetector website, WhatsApp was inaccessible for around 11,708 people at around 9.11 PM. After the chat app faced an outage, several users took to social media platform X to confirm the development. “didn’t even notice WhatsApp is down,” a user wrote. Another user said that he was trying to reboot his phone for one hours wondering if his phone is having an issue. “I have been trying to reboot my phone for 1 hour now thinking my phone had an issue…only to find out from you guys that my phone is WhatsApp is down,” he said. A user found the funny side of it and said, ” Many people are saying WhatsApp is down, but my is still working very well Or I my using the wrong WhatsApp?”. In another development, the Maharashtra government on Friday announced that more than 500 services from its ‘Aaple Sarkar’ portal will now be available through WhatsApp. Chief Minister Devendra Fadnavis made the announcement during the inauguration of `Mumbai Tech Week 2025′ here, where an MoU was signed between the state’s Information Technology Department and Meta, which owns WhatsApp. Additionally, an agreement was signed between the Mumbai Metropolitan Region Development Authority and the National Payments Corporation of India (NPCI) for allotment of land in the Bandra Kurla Complex here for the NPCI’s global headquarters. A `Knowledge AI Hub’ will be established in collaboration with TEAM to promote advancements in artificial intelligence, an official statement said. The government also announced the establishment of an Entrepreneurship Museum to inspire and support start-ups.

Indian businessman Adil Qumar Akhtar, a UAE Golden Visa holder, is under investigation for alleged financial and identity fraud spanning multiple countries. Operating from Dubai under the guise of a real estate entrepreneur, Akhtar is accused of forging identities, defrauding investors, and misusing financial networks. Authorities in India and the UAE are now on high alert as reports suggest his possible links to organized crime. Passport Fraud: Manipulating Indian Regulations Investigations reveal that Akhtar, originally from Barauni, Bihar, obtained an Indian passport in Mumbai (August 2023) using a fraudulent residential address. This act violates Section 12 of the Indian Passport Act, 1967, allowing him to move freely between India and the UAE while evading scrutiny. Concealing Marital Status for Immigration Benefits Authorities also found discrepancies in Akhtar’s marital status. While undisclosed in India, he reported it in the UAE, possibly to exploit residency benefits. This raises concerns over immigration loopholes that may be enabling other fugitives to misuse similar tactics. Fraudulent UAE Golden Visa Acquisition Akhtar secured his UAE Golden Visa in October 2024, a status reserved for top investors and professionals. Reports indicate he concealed key details and submitted false documents to obtain it, allowing access to financial networks and international investments. Links to Drug Syndicates & UAE Escape Authorities suspect Akhtar’s ties to convicted Dubai-based drug trafficker Tanya Suryavanshi. Following a crackdown, he fled Dubai with an associate, Abhishek Jha, on November 29, 2024. His escape is seen as an attempt to avoid prosecution for financial fraud and possible drug-related charges. Where is Adil Qumar Akhtar Now? While Suryavanshi remains in Dubai’s custody, Akhtar and Jha are reportedly hiding in India. Interpol and UAE officials are working to track them down, but Akhtar continues to operate under false pretenses, falsely claiming to be Chief Business Development Officer at Everbridge Shipping LLC, Dubai. Authorities Question Possible Protection Despite mounting evidence, Akhtar remains at large, raising concerns about possible local protection. With stolen funds at his disposal, authorities are investigating whether he has secured immunity through corruption. This case highlights urgent gaps in cross-border fraud detection and calls for stronger cooperation between Indian and UAE agencies. Authorities must act swiftly before Akhtar disappears once again.